Happel David 4

What Happened
David Happel, President & CEO and a director of Sagimet Biosciences (SGMT), was granted an award of 300,000 derivative shares/options on May 28, 2026. The Form 4 reports a $0.00 per-share acquisition price (no cash paid at grant is reported). This was a grant/award (not a market purchase or sale) and does not represent an immediate sale or exercise.

Key Details

• Transaction date: May 28, 2026; Form 4 filed June 1, 2026 (filed within the standard two-business-day window).
• Amount: 300,000 derivative shares/options; reported acquisition price $0.00 (no cash outlay reported at grant).
• Vesting/exercise: Footnote states the shares underlying the option vest and become exercisable in 48 equal monthly installments beginning May 28, 2026, subject to continued service.
• Shares owned after transaction: Not specified in the provided filing.
• Filing timeliness: Timely (filed June 1, 2026 for a May 28 transaction).

Context
This was a time-based equity award to an executive, not a purchase or sale. For derivative grants like this, value to the insider depends on future stock performance and the option’s exercise terms once vested; no shares were reported as exercised or sold in this filing. Such awards are common for executive compensation and serve as long-term incentives rather than immediate market activity.